# Agency Forms Undergoing Paperwork Reduction Act Review > Briefs, arguments, decisions, and more. URL: https://www.frixlaw.com/law-library/documents/fr%3A97-1475 ## Record - **Collection:** Federal Register - **Document type:** Notice - **Published:** January 22, 1997 - **Citation:** 62 FR 3292 ## Text DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [30 DAY-26] Agency Forms Undergoing Paperwork Reduction Act Review The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the CDC Reports Clearance Office on (404) 639-7090. Send written comments to CDC, Desk Officer; Human Resources and Housing Branch, New Executive Office Building, Room 10235; Washington, DC 20503. Written comments should be received within 30 days of this notice. The following requests have been submitted for review since the last publication date on January 16, 1997. Proposed Project Studies of Immunotoxicity in Occupational Groups--(0920-0333)-- Reinstatement--A number of chemicals to which U.S. workers are potentially exposed, including metals such as lead and beryllium and solvents such as carbon tetrachloride, have been found to be immunotoxic in experimental animals. There is little data on immunosuppression, hypersensitivity or autoimmune disease in workers exposed to chemicals that are immunotoxic in experimental animals. NIOSH has undertaken a coordinated series of studies to focus on immune-system effects related to specific chemical exposures in the workplace. In the previous three years, NIOSH conducted studies of lead and egg protein exposed workers. In this reinstatement of the program, it is anticipated that up to six additional research studies will be conducted under this program. Examples of chemicals for which studies are being considered are latex, silica, and solvents. In most of these studies, the immune function of a group of workers exposed to the chemical of interest, and not exposed to any other known or potential immunotoxins, will be compared to the immune function in a group of individuals with no occupational exposure to known or suspected immunotoxins. In some studies, the immune function in a group of individuals will be compared before and after they have exposure to the potential immunotoxin. The primary information collected will be data on the level of exposure to the potential immunotoxin (as measured in the air in the breathing zone of the respondent, and/or in the respondent's blood or urine) and data on specific markers of the status of the immune system from blood or saliva samples provided by the subjects. The questionnaire data will be directed at demographic, lifestyle, and medical factors (other than the exposure or condition of interest) which may influence the function of the immune system. In selected studies, the questionnaire will be used to assess the presence of respiratory symptoms, dermatologic conditions and/or reproductive effects, if the literature indicates a potential relationship to these health problems. Study populations will be identified through telephone contact and follow-up site visits (if needed) with workplace facilities that use the chemical of interest. The total annual burden is 1607. ---------------------------------------------------------------------------------------------------------------- Avg. No. of burden/ Respondent (form) No. of responses/ response Total burden respondents respondent (in (in hrs.) hrs.) ---------------------------------------------------------------------------------------------------------------- Interview and blood collection.............................. 600 1 1 600 Additional interview module (respiratory, dermatologic, or reproductive).............................................. 600 1 .5 300 Peak flow measurement (hypersensitivity studies only)....... 200 28 .08 467 Allergy skin tests (hypersensitivity studies only).......... 200 1 1 200 Company interview........................................... 40 1 1 40 ---------------------------------------------------------------------------------------------------------------- Dated: January 15, 1997. William G. Johnson, Acting Associate Director for Policy Planning and Evaluation, Centers for Disease Control and Prevention (CDC). [FR Doc. 97-1475 Filed 1-21-97; 8:45 am] BILLING CODE 4163-18-P --- Source: Frix Law Library, https://www.frixlaw.com/law-library/documents/fr%3A97-1475. Public record. Not legal advice.